河北医药
河北醫藥
하북의약
Hebei Medical Journal
2015年
20期
3061-3063
,共3页
冠心病%vWF-CP%GDF15%相关性
冠心病%vWF-CP%GDF15%相關性
관심병%vWF-CP%GDF15%상관성
coronary heart disease%vWF-CP%GDF15%correlation
目的：探讨冠心病患者血浆血管性血友病因子裂解酶（vWF-CP）、生长分化因子-15（GDF-15）的改变以及临床意义。方法选取2012年2月至2014年7月治疗的冠心病患者104例，其中稳定型心绞痛患者48例（ SAP组），急性冠脉综合征患者56例（ ACS组），同时选取类心绞痛患者43例为对照组，检测各组患者血浆vWF-CP、GDF15以及生化指标如总胆固醇（TC）、低密度脂蛋白胆固醇（LDL-C）、高密度脂蛋白胆固醇（HDL-C）等。结果 SAP组、ACS组和对照组TC、LDL-C、HDL-C、血肌酐（Cr）和天冬氨酸氨基转移酶（AST）等差异无统计学意义（ P ＞0\．05）；对照组患者血浆 vWF-CP 为（612．18±24．07） pg／ml，高于 SAP 组和 ACS 组，而 SAP 组血浆 vWF-CP 为（373．13±24．09）pg／ml，高于ACS组的（276．39±23．18）pg／ml，3组差异有统计学意义（ P ＜0．05）；对照组患者血浆GDF15为（1．42±0．37）ng／ml，低于 SAP组和ACS组，而SAP组血浆GDF15为（7．93±0．67） ng／ml，低于ACS组（10．02±0．92）ng／ml，3组差异有统计学意义（ P ＜0．05）；冠心病患者血浆vWF-CP和GDF15水平呈负相关（ r ＝－0．702，P＜0．05）。结论冠心病患者血浆血管性vWF-CP和GDF15存在相关性，且可在临床上用于预测冠心病患者的风险。
目的：探討冠心病患者血漿血管性血友病因子裂解酶（vWF-CP）、生長分化因子-15（GDF-15）的改變以及臨床意義。方法選取2012年2月至2014年7月治療的冠心病患者104例，其中穩定型心絞痛患者48例（ SAP組），急性冠脈綜閤徵患者56例（ ACS組），同時選取類心絞痛患者43例為對照組，檢測各組患者血漿vWF-CP、GDF15以及生化指標如總膽固醇（TC）、低密度脂蛋白膽固醇（LDL-C）、高密度脂蛋白膽固醇（HDL-C）等。結果 SAP組、ACS組和對照組TC、LDL-C、HDL-C、血肌酐（Cr）和天鼕氨痠氨基轉移酶（AST）等差異無統計學意義（ P ＞0\．05）；對照組患者血漿 vWF-CP 為（612．18±24．07） pg／ml，高于 SAP 組和 ACS 組，而 SAP 組血漿 vWF-CP 為（373．13±24．09）pg／ml，高于ACS組的（276．39±23．18）pg／ml，3組差異有統計學意義（ P ＜0．05）；對照組患者血漿GDF15為（1．42±0．37）ng／ml，低于 SAP組和ACS組，而SAP組血漿GDF15為（7．93±0．67） ng／ml，低于ACS組（10．02±0．92）ng／ml，3組差異有統計學意義（ P ＜0．05）；冠心病患者血漿vWF-CP和GDF15水平呈負相關（ r ＝－0．702，P＜0．05）。結論冠心病患者血漿血管性vWF-CP和GDF15存在相關性，且可在臨床上用于預測冠心病患者的風險。
목적：탐토관심병환자혈장혈관성혈우병인자렬해매（vWF-CP）、생장분화인자-15（GDF-15）적개변이급림상의의。방법선취2012년2월지2014년7월치료적관심병환자104례，기중은정형심교통환자48례（ SAP조），급성관맥종합정환자56례（ ACS조），동시선취류심교통환자43례위대조조，검측각조환자혈장vWF-CP、GDF15이급생화지표여총담고순（TC）、저밀도지단백담고순（LDL-C）、고밀도지단백담고순（HDL-C）등。결과 SAP조、ACS조화대조조TC、LDL-C、HDL-C、혈기항（Cr）화천동안산안기전이매（AST）등차이무통계학의의（ P ＞0\．05）；대조조환자혈장 vWF-CP 위（612．18±24．07） pg／ml，고우 SAP 조화 ACS 조，이 SAP 조혈장 vWF-CP 위（373．13±24．09）pg／ml，고우ACS조적（276．39±23．18）pg／ml，3조차이유통계학의의（ P ＜0．05）；대조조환자혈장GDF15위（1．42±0．37）ng／ml，저우 SAP조화ACS조，이SAP조혈장GDF15위（7．93±0．67） ng／ml，저우ACS조（10．02±0．92）ng／ml，3조차이유통계학의의（ P ＜0．05）；관심병환자혈장vWF-CP화GDF15수평정부상관（ r ＝－0．702，P＜0．05）。결론관심병환자혈장혈관성vWF-CP화GDF15존재상관성，차가재림상상용우예측관심병환자적풍험。
Objective To investigate the changes and clinical significance of von Willebrand factor cleaving protease (vWF-CP) and growth differentiation factor-15 (GDF15) levels in patients with coronary heart disease (CHD).Methods One hundred and four patients with CHD who were treated in our hospital from February 2012 to July 2014 were enrolled in the study,including 48 patients with stable angina pectoris (SAP group), and 56 patients with acute coronary syndrome (ACS group) ,at the same time, the other 43 patients with similar angina pectoris were served as control group.The plasma levels of vWF-CP, GDF15 and biochemical parameters including total cholesterol ( TC) ,low density lipoprotein cholesterol ( LDL-C) , high density lipoprotein cholesterol ( HDL-C ) were detected for the three groups.R seults There were no significant differences in the levels of TC,LDL-C,HDL-C,Cr and AST between SAP group,ACS group and control group ( P >0.05). The plasma vWF-CP in control group was (612.18 ±24.07) pg/ml, which was significantly higher than that of SAP group and ACS group,moreover, plasma vWF-CP in SAP group was (373.13 ±24.09)pg/ml,which was significantly higher than that of ACS group (276.39 ±23.18)pg/ml ( P <0.05).The plasma GDF15 in control group was (1.42 ±0.37)ng/ml, which was significantly lower than that in SAP group or ACS group ,however,plasma GDF15 in SAP group was (7.93 ±0.67) ng/ml,which is significantly lower than that of ACS group (100.2 ±0.92)ng/ml ( P <0.05).The plasma levels of vWF -CP were negatively correlated to those of GDF15 ( r =-0.702, P <0.05).Conclusion There is a correlation between plasma vWF-CP and vascular GDF15 in patients with CHD,which can be used to predict the risk of patients with CHD in clinic.
